|
 |
| home > ebr > Summer 2003 |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue |
|
|
|
| Dr Helen Abbott, Senior Consultant at Technomark, reviews Ernst and Young's European Biotechnology Report 2003, Endurance: European Biotech - Surviving the Storm |
|
|
| Morten Soegaard, Research Analyst at Frost & Sullivan, identifies routes to Maximising Return on Investment with R&D Portfolio Management |
|
|
| Pharmaceutical companies are finding it increasingly difficult to boost the output of new drugs. In Biotechnology: Breathing New Life into Drug Development, Faiz Kermani, Budgets, Proposals and Marketing Executive, and Pietro Bonacossa, Marketing Executive, at Chiltern International Inc, provide some potential answers |
|
|
|
|
| The era of 'super vaccines' could be just around the corner, mitigating everything from herpes, to cancers and even AIDS. Biotech industry guru G Steven Burrill, CEO of Burrill & Company, leads us through The Future of Vaccines |
|
|
| In Giving Vaccines the Boost They Need, we look at the innovations behind today's vaccine industry with Dr Deirdre Gillespie, President and Chief Executive Officer at Oxxon PharmaccinesTM Ltd |
|
|
| More people in their 60s and beyond are falling victim to conditions such as Alzheimer's, Parkinson's and stroke. Dr Itzchak Angel, Vice President Research and Development at D-Pharm Ltd, examines the battle against Losing Our Minds - What the Future Holds for the Treatment of Neurodegenerative Disorders |
|
|
| As the mortality rate for SARS reaches some 15 per cent, we consider Fighting SARS in the Post-Genomic Era with Professor Yike Guo, Technical Director of the Parallel Computing Centre and Head of the Data Mining Group of Imperial College, and Dr Wayne He, Director of SCBIT-IBM-InforSense Joint Laboratory of the Shanghai Center for Bioinformation Technology (SCBIT) |
|
|
| Meanwhile, Dr George Rowland, Chairman and Co-Founder of ZinCare International Ltd investigates The Potential of Zinc Ions for Prophylaxis and Treatment of Severe Acute Respiratory Syndrome (SARS) |
|
|
|
|
| Dr Michael I Ugwoke, Scientist Formulation Development/Project Leader, and Professor Daan JA Crommelin, Scientific Director at OctoPlus Development BV, explain Biopharmaceuticals: A Special Breed of Drugs |
|
|
| Dr Mark Millichip, HPLC Applications Technical Support Specialist at Polymer Laboratories Ltd, asks Are 'Polymerics' Coming of Age? |
|
|
| Perspectives in Preclinical Development are offered by Thomas Allen, Director of Allen Preclinical Consultants GmbH |
|
|
| With demand increasing, Dr Stephen Little, CEO of DxS Ltd, examines How to Include Genetic Analysis in Clinical Trials |
|
|
| What happens when breakthrough biotech products are so successful they overwhelm manufacturing capacity? Geoff Tomlinson, Principal and Hannes Kunz, Director of PRTM, look at Managing your Way Out of the Success Trap |
|
|
| Didn't attend? Read the review - SMi Conference London March 2003, Biologics: Overcoming the Challenges of Development and Manufacture |
|
|
|
| In The Cognitive Assessment of Herbal Products - Are the Effects Imagined or Real? Tamsin Manktelow, Scientific Development Manager, and Andrea Zangara, Research Associate, at Cognitive Drug Research Ltd, guide us through new EU legislation and its impact on traditional herbal remedies |
|
|
| Sean Flanagan, Commercial Director at Kryotrans Ltd, and Adrian Shaw, Partner at Ikon Associates, outline Cold Chain: Risk, Regulatory Compliance and Operational Performance |
|
|
| Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences, ask Preclinical Juvenile Toxicity Studies: Will it be Safe for Children? |
|
|
|
| In the race to bring new biotech derived products to market, researchers face many obstacles along the road from discovery to commercial success. Dr Fiona M Greer, Director, Biochemical Services at M-Scan Ltd, answers some queries about the use of mass spectrometry in Biopharmaceutical Characterisation - Considering Key Questions |
|
|
| Ralf Moritz, Application Chemist at Agilent Technologies and Nicola O'Reilly at Cancer Research UK, look at Mass-Based Fraction Collection of Crude Synthetic Peptides in Analytical and Preparative Scale for cancer treatment |
|
|
| In Making the Remarkable Routine, Professor Alan Marshall, National High Magnetic Field Laboratory at Florida State University, USA and Dr Alan Street, Oxford Instruments Superconductivity, at Oxford Instruments, UK, consider high-field FT-ICR MS - a powerful technique for composition and structural analysis |
|
|
| As the advent of proteomics switches the emphasis from genes to proteins, increased scientific attention is being paid to techniques that produce detailed information on human proteins. Dr Stefan Lofus, Vice President and Chief Scientific Officer at Biacore AB, evaluates one such technique in SPR-MS in Functional Proteomics |
|
|
| Christophe Fraudeau, Marketing Manager at Jouan Robotics, charts Trends in Laboratory Robotics in the Biopharmaceutical Industry |
|
|
|
| Nika V Ketis, Lawyer at Bennett Jones, examines The Baker Case and Eight-Part Test for Considering Disclosure by Prior Use or Sale |
|
|
| Are Patents the Beating Heart of your Boardroom? Ian Harvey, Chief Executive Officer of BTG plc and Chairman of the Government's Intellectual Property Advisory Committee, explains why they should be |
|
|
|
| As the official publication for CORDIA - EuropaBio Convention 2003, we bring you all the news and views on Europe's first comprehensive life science convention to be held this December |
|
|
|
| Geoff Parker, Commercial Director at Scimcon, balances biological research against computer-based research in The Biotech Juggling Act |
|
|
| Collaborative drug discovery decisions from diverse locations in real-time? Dan Stevens, Marketing Manager, Life and Chemical Sciences at SGI, welcomes us to Visualisation in Drug Discovery: The Way of the Future |
|
|
|
| Rudy Aernoudt, Deputy Head of Cabinet of the Walloon Ministry for Economy and Research, brings us The Blossoming of Biotechnology in Wallonia |
|
|
|
| Jeanette Walker, Business Development Director at ERBI, sheds light on Cambridge, England - Europe's Low Risk Biotech Location |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
New PFA SonicLineŽ ultrasonic flowmeters
Flow measurement with ultrasound fast, precise, free from contamination The new PFA SonicLineŽ ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLineŽ is also ideally suited for accurate batch and dosing processes with high reproducibility.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
